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Background: In the Emergency Department (ED), diagnosis and management of anaphylaxis
are challenging with at least 50% of anaphylaxis episodes misdiagnosed when the diagnostic
criteria of current guidelines are not used.
Objective: Objective of our study was to assess anaphylaxis diagnosis and management in
patients presenting to the ED.
Methods: Retrospective chart review conducted on patients presenting to The Medical City
Hospital ED, the Philippines from 2013–2015 was done. Cases were identified based on
International Statistical Classification of Diseases, 10th revision coding for either anaphylaxis
or other allergic related diagnosis. Cases fitting the definition of anaphylaxis as identified by
the National Institute of Allergy and Infectious Disease and the Food Allergy and Anaphylaxis
Network (NIAID/FAAN) were included. Data collected included demographics, signs and
symptoms, triggers and management.
Results: A total of 105 cases were evaluated. Incidence of anaphylaxis for the 3-year
study period was 0.03%. Of the 105 cases, 35 (33%) were diagnosed as “urticaria” or
“hypersensitivity reaction” despite fulfilling the NIAID/FAAN anaphylaxis criteria. There was
a significant difference in epinephrine administration between those given the diagnosis of
anaphylaxis versus misdiagnosed cases (61 [87%] vs. 12 [34%], χ2 = 30.77, p < 0.01); and a
significant difference in time interval from arrival at the ED to epinephrine administration,
with those diagnosed as anaphylaxis (48%) receiving epinephrine within 10 minutes, versus ≥
60 minutes for most of the misdiagnosed group (χ2 = 52.97, p < 0.01).
Conclusion: Despite current guidelines, anaphylaxis is still misdiagnosed in the ED.
Having an ED diagnosis of anaphylaxis significantly increases the likelihood of epinephrine
administration, and at a shorter time interval.
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INTRODUCTION
Anaphylaxis is now universally defined as a serious allergic reaction that is rapid in onset
and can cause death [1]. It is a medical emergency affecting more people in different parts of
the world, with overall mortality risk estimated at 1%. In the 2015 updates on epidemiology
of anaphylaxis, the Word Allergy Organization (WAO) reported that hospitalizations due to
anaphylaxis have been increasing [1-3].
Several studies have attempted to establish the true incidence of anaphylaxis in the
Emergency Department (ED). Previously, the absence of a universal definition of anaphylaxis
leading to variations in the interpretation and then underreporting and miscoding, made
research on this disease difficult and inaccurate. In July 2005, the National Institute of Allergy
and Infectious Disease and the Food Allergy and Anaphylaxis Network (NIAID/FAAN) created
a universally accepted definition and criteria for diagnosis and guidelines on the management
of anaphylaxis [1]. These clinical criteria for the diagnosis of anaphylaxis have been validated
in ED studies in children, teenagers, and adults as having high sensitivity (96.7%), reasonable
specificity (82.4%), and a high negative predictive value (98%) [1, 4, 5].
In the ED, diagnosis and management of anaphylaxis remains challenging because symptoms
are nonspecific, may resemble other conditions, and appears and progresses rapidly after
exposure to a trigger [1]. There has been no known laboratory test which can confirm or
rule out diagnosis of anaphylaxis, which could then promptly aid in the decision making on
treatment upon arrival of a patient at the ED. The diagnosis of anaphylaxis thus largely relies
upon the history and physical examination of the attending health professional [6]. It has
been estimated that at least 50% of anaphylaxis episodes are misdiagnosed in the ED when
the diagnostic criteria of current guidelines are not used [7].
The objective of the present study was to determine the incidence of anaphylaxis in the ED
of a tertiary care hospital in the Philippines as identified by the NIAID/FAAN Criteria, and
describe characteristics of these anaphylaxis cases, their management and outcomes.

MATERIALS AND METHODS
Study design
This study was a retrospective descriptive research, using chart review to identify and
describe cases of anaphylaxis seen at the ED of The Medical City Hospital, a tertiary hospital
in a major city in the Philippines.
Purposive sampling and complete enumeration of all cases of anaphylaxis identified
through the hospital electronic records was done. All records of patients seen at ED from
January, 2013 to December, 2015 with specific International Statistical Classification of
Diseases, 10th revision (ICD-10) codes including (1) anaphylactic shock due to adverse food
reaction T78.0, (2) anaphylactic shock, unspecified T78.2, (3) angioneurotic edema T78.3,
(4) allergic reaction, not otherwise specified, hypersensitivity not otherwise specified
T78.4, (5) anaphylactic shock due to adverse effect of correct drug or medicament properly
administered T78.6, (6) allergic urticaria L50.0, (7) idiopathic urticaria L50.1, (8) urticaria
unspecified L50.9, and (9) generalized skin eruption due to drug and medicaments L27.0,
were reviewed.
https://apallergy.org
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The study was approved by the Institutional Review Board of The Medical City Hospital
(approval number: GCS Ped 2016-013).

Study population
The 2 authors reviewed together all the charts identified. Study population included all
pediatric (age < 18 years) and adult (age ≥ 18 years) cases of anaphylaxis seen at the ED from
January 2013 to December 2015, who satisfied the 2005 NIAID/FAAN clinical criteria for
the diagnosis of anaphylaxis, regardless of the initial diagnosis assigned to them in the ED
report. The 2005 NIAID/FAAN clinical criteria were used as this was the criteria included
in the ED manual of the hospital at the time the study was done. These identified cases of
anaphylaxis were divided into 2 groups: (1) diagnosed as anaphylaxis or (2) not diagnosed as
anaphylaxis/other allergy-related diagnosis at ED.
We recorded demographic data, clinical symptoms, treatment received, triggers suspected by
the patient and the ED physician, outcome of the anaphylactic episode, and the final diagnosis.
Patients who did not satisfy the NIAID/FAAN criteria for diagnosing anaphylaxis were
excluded from the study.
The number of patients admitted daily to the ED was also recorded.

Statistical analysis
Descriptive statistics used in this study were the following: frequency, percentage, mean
and range. Chi-square was used to determine whether epinephrine administration and time
interval of administration from time of arrival at ED were dependent on the diagnosis, and
whether diagnosis was dependent on specific clinical features.

RESULTS
Incidence of anaphylaxis
Out of the 344,823 pediatric and adult patients seen at the ED from January 2013 to December
2015, a total of 105 cases of anaphylaxis were identified using the NIAID/FAAN criteria. There
was only one readmitted patient due to anaphylaxis; the second episode occurring 1 year
after. Thus, the study gathered 105 cases of anaphylaxis in 104 patients. Incidence rate for the
3-year study period was 0.03% or 0.34 episodes per 1,000 ED visit.
Out of 105 cases, 66.7% were diagnosed as anaphylaxis, while 33.3% were diagnosed as other
allergy-related disease: “hypersensitivity reaction” (18.1%) or “urticaria” (15.2%). All patients
diagnosed as anaphylaxis fit the criteria of NIAID/FAAN.

Characteristic of the study population
Among anaphylaxis cases, 55.2% were females. There was an almost equal distribution of
cases between pediatric (49.6%) and adult (50.4%) age groups. Among anaphylaxis cases,
11.4% had at least one previous episode of anaphylaxis. Majority (77.1%) had history of atopy,
while 50.5% had family history of atopy (Table 1).
A previous history of anaphylaxis had no effect on whether the patients were eventually
diagnosed with anaphylaxis or not (Table 2).
https://apallergy.org
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Table 1. Patient characteristics (n = 105)
Characteristic
No. of cases (%)
Sex
Male
47 (44.8)
Female
58 (55.2)
Age (yr)
0–5
7 (6.7)
6–9
9 (8.6)
10–18
36 (34.3)
19–29
18 (17.1)
30–39
15 (14.3)
40–59
14 (13.3)
≥60
6 (5.7)
With history of anaphylaxis
12 (11.4)
History of atopic disease
81 (77.1)
Asthma
32 (30.5)
Food allergy
44 (41.9)
Drug allergy
24 (22.9)
Allergy aside from food and drugs
7 (6.7)
Allergic rhinitis
8 (7.6)
Atopic dermatitis
3 (2.9)
Family history of atopy
53 (50.5)
Intake of medications
ACE inhibitors
5 (4.8)
Beta blockers
4 (3.8)
NSAID
1 (0.9)
Medical comorbidity
17 (16.2)
Hypertension
14 (13.3)
Other cardiovascular disease
2 (1.9)
ACE, angiotensin-converting-enzyme; NSAID, nonsteroidal anti-inflammatory drug.
Table 2. Diagnosis of anaphylaxis in relation to history of anaphylaxis
History of anaphylaxis
Anaphylaxis cases
Diagnosed as
Not diagnosed as
anaphylaxis at ED
anaphylaxis at ED
No
62 (66.7)
31 (33.3)
Yes
8 (66.7)
4 (33.3)
Total
70 (66.7)
35 (33.3)
Values are presented as number (%).
ED, Emergency Department.
χ2 = 0.0, p > 0.05.

Total

93 (88.6)
12 (11.4)
105 (100)

In both age groups, majority had no identifiable obvious cause (38.1%) (Table 3). In those
that had an identifiable trigger based on history alone, the most common were food (34.3%)
and drugs (20%). The diagnosis of anaphylaxis was independent of the triggers identified
The most frequently involved organs were that of the skin and lungs. Difficulty of breathing
was the most common chief complaint (48.6%) and overall symptom (90.5%). Pruritus
was the most common skin symptom (85.7%) (Table 4). The diagnosis of anaphylaxis was
shown to be dependent on the presence of specific symptoms such as wheezing, low oxygen
saturation, hypotension, and abdominal pain (Table 5).

Management of anaphylaxis
Fig. 1 shows epinephrine administration between the cases diagnosed versus those not
diagnosed as anaphylaxis. Seventy-three cases (69.5%) received epinephrine. Significantly
more patients were given epinephrine when given the diagnosis of anaphylaxis as compared
to those who were not (61,87.1% vs. 12, 34.3%, χ2 = 30.767, p < 0.01).
https://apallergy.org
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Table 3. Identified triggers of anaphylaxis
Trigger of anaphylaxis
Food
Crustacean
Fish
Peanut
Chicken
Sesame seed
Raisin
Fried rice
Chocolate
Noodles
Drugs
NSAID
Paracetamol
Amoxicillin
Coamoxiclav (amoxicillin + clavulanic acid)
Cefalexin
Probiotics
Hyoscine
Radiocontrast media
Rabies vaccine
Insect bite/sting
Unknown
Values are presented as number (%).
NSAID, nonsteroidal anti-inflammatory drug.
χ2 = 3.788, p > 0.05.

Child (n = 52)
19 (18)
7 (6.6)
3 (2.8)
5 (4.8)
1 (1)
0 (0)
0 (0)
1 (1)
1 (1)
1 (1)
10 (9.5)
5 (4.8)
1 (1)
1 (1)
2 (1.9)
0 (0)
1 (1)
0 (0)
1 (1)
0 (0)
1 (1)
21 (2)

Adult (n = 53)
17 (16.1)
9 (8.6)
3 (2.8)
0 (0)
3 (2.8)
1 (1)
1 (1)
0 (0)
0 (0)
0 (0)
11 (10.5)
6 (5.7)
1 (1)
1 (1)
1 (1)
1 (1)
0 (0)
1 (1)
1 (1)
1 (1)
4 (3.8)
19 (18.1)

Total (n = 105)
36 (34.3)
16 (15.2)
6 (5.7)
5 (4.8)
4 (3.8)
1 (1)
1 (1)
1 (1)
1 (1)
1 (1)
21 (20)
11 (10.4)
2 (1.9)
2 (1.9)
3 (2.8)
1 (1)
1 (1)
1 (1)
2 (1.9)
1 (1)
5 (4.8)
40 (38.1)

Most epinephrine doses were given via intramuscular route (87.6%). Other routes used
include subcutaneous (5.5%), inhalation via nebulization (4.1%), intravenous bolus (1.4%),
and continuous intravenous drip for a patient diagnoses with anaphylactic shock (1.4%).
Majority of cases diagnosed as anaphylaxis (47.5%) received epinephrine within less than 10
minutes from time of arrival at ED. Of the patients who were not diagnosed as anaphylaxis,
more than half (58.3%) eventually received epinephrine but only after 60 minutes (Fig. 2).
Table 6 shows the rest of the management plans for the patients, including other medications
given aside from epinephrine, referral to an allergist, and the disposition after being
discharged from the ED. There was no difference in the referral rates whether the patients
were initially diagnosed as anaphylaxis or not. The 14 patients who were admitted at the
80

No epinephrine
Given epinephrine

No. of anaphylaxis cases

70
60
50
40

61

30

12

20
10
0

23
9
Diagnosis as anaphylaxis at ED

Not diagnosis as anaphylaxis at ED

Fig. 1. Epinephrine administration in anaphylaxis cases. ED, Emergency Department. χ2 = 30.767, p < 0.01.
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Table 4. Chief complaint and signs and symptoms of anaphylaxis cases
Variable
No. of cases (n = 105)
Chief complaints
Difficulty of breathing
51 (48.6)
Rashes
31 (29.5)
Eye swelling
11 (10.5)
Chest pain/tightness
3 (2.9)
Throat discomfort
2 (1.9)
Generalized body weakness
3 (2.9)
Loss of consciousness
1 (1)
Abdominal pain
1 (1)
Nausea
1 (1)
Dizziness
1 (1)
Signs and symptoms
Respiratory
Difficulty of breathing
95 (90.5)
Wheezing
68 (64.8)
O2 saturation < 95%
22 (21)
Cough
14 (13.3)
Rhinorrhea
11 (10.5)
Choking
4 (3.8)
Stridor
1 (1)
Skin
Pruritus
90 (85.7)
Urticaria
61 (58.1)
Flushing
43 (41)
Periorbital edema
37 (35.2)
Erythema
12 (11.4)
Conjunctival redness
9 (8.6)
Lip swelling
8 (7.6)
Tearing
7 (6.7)
Cardiovascular
Tachycardia
55 (52.4)
Hypotension
17 (16.2)
Chest pain
17 (16.2)
Syncope
6 (5.7)
Arrhythmia
3 (2.9)
Palpitation
4 (3.8)
Gastrointestinal
Abdominal pain
17 (16.2)
Vomiting
15 (14.3)
Diarrhea
4 (3.8)
Nausea
2 (1.9)
Central nervous system
Dizziness
7 (6.7)
Weakness
5 (4.8)
Headache
1 (1)
Values are presented as number (%).

intensive care unit (13.3%), all presented with hypotension at the ED. All admitted cases were
discharged stable, mostly after 1 day of hospital stay. There were no cases of mortality among
admitted patients.

DISCUSSION
There are few data on the incidence of anaphylaxis. Incidence rate calculated in our study was
0.03%, which was comparable to studies done in hospitals in Bangkok, Pakistan and Spain of
0.01%–0.08% [6, 8, 9].
https://apallergy.org
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Table 5. Diagnosis of anaphylaxis in relation to presence of symptoms
Symptom
Anaphylaxis cases
Diagnosed as
Not diagnosed as
anaphylaxis at ED
anaphylaxis at ED
Difficulty of breathing
Absent
5 (50)
5 (50)
Present
65 (68.4)
30 (31.6)
Total
70 (66.7)
35 (33.3)
Wheezing
Absent
20 (54.1)
17 (45.9)
Present
50 (73.5)
18 (26.5)
Total
70 (66.7)
35 (33.3)
O2 saturation < 95%
Absent
51 (61.4)
32 (38.6)
Present
19 (86.4)
3 (13.6)
Total
70 (66.7)
35 (33.3)
Urticaria
Absent
33 (75)
11 (25)
Present
37 (60.7)
24 (39.3)
Total
70 (66.7)
35 (33.3)
Flushing
Absent
41 (66.1)
21 (33.9)
Present
29 (67.4)
14 (32.6)
Total
70 (66.7)
35 (33.3)
Periorbital edema
Absent
43 (63.2)
25 (36.8)
Present
27 (73)
10 (27)
Total
70 (66.7)
35 (33.3)
Tachycardia
Absent
33 (66)
17 (34)
Present
37 (67.3)
18 (32.7)
Total
70 (66.7)
35 (33.3)
Hypotension
Absent
55 (62.5)
33 (37.5)
Present
15 (88.2)
2 (11.8)
Total
70 (66.7)
35 (33.3)
Chest pain
Absent
60 (68.2)
28 (31.8)
Present
10 (58.8)
7 (41.2)
Total
70 (66.7)
35 (33.3)
Abdominal pain
Absent
65 (73.9)
23 (26.1)
Present
5 (29.4)
12 (70.6)
Total
70 (66.7)
35 (33.3)
Vomiting
Absent
59 (65.6)
31 (34.4)
Present
11 (73.3)
4 (26.7)
Total
70 (66.7)
35 (33.3)
Values are presented as number (%).
ED, Emergency Department.

χ2 (p value)
Total
1.382 (>0.05)
10 (9.5)
95 (90.5)
105 (100)
37 (35.2)
68 (64.8)
105 (100)

4.090 (<0.05*)

4.859 (<0.05*)

83 (79)
22 (21)
105 (100)
2.367 (>0.05)
44 (41.9)
61 (58.1)
105 (100)
0.020 (>0.05)
62 (59)
43 (41)
105 (100)
1.022 (>0.05)
68 (64.8)
37 (35.2)
105 (100)
0.019 (>0.05)
50 (47.6)
55 (52.4)
105 (100)

4.246 (<0.05*)

88 (83.8)
17 (16.2)
105 (100)
0.561 (>0.05)
88 (83.8)
17 (16.2)
105 (100)

12.669 (<0.01*)

88 (83.8)
17 (16.2)
105 (100)
0.350 (>0.05)
90 (85.7)
15 (14.3)
105 (100)

Studies on the epidemiology of anaphylaxis were hampered by a lack of consensus on the
definition and criteria for its diagnosis. This was until recently when in 2005 the NIAID/FAAN
established a consensus on the definition and diagnostic criteria to satisfy epidemiological,
research, and clinical needs. Accurate diagnosis was also hindered by the lack of accurate
diagnostic coding. Our study used the ICD-10 codes for anaphylaxis and allergy-related
disorders to search for the charts that we reviewed. The ICD version used matter because
reports show that anaphylaxis incidence varied between studies using the 9th or 10th ICD
codes as selection criteria of cases using the NIAID/FAAN criteria [10]. Other studies have
https://apallergy.org
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35

No. of anaphylaxis cases

30

Diagnosis as anaphylaxis at ED
Not diagnosis as anaphylaxis at ED

0
5

25
20
15

29

25

10
0

5
0

6
<10

10 to <30

30 to <60

7
1
≥60

Time interval (min)
Fig. 2. Time interval from arrival at Emergency Department (ED) to administration of epinephrine. χ2 = 2.969, p < 0.05.

likewise shown that the available codes were not very helpful when attempting to describe
anaphylaxis [11-13], and there was also an insufficient number of codes available to document
episodes of diagnosed anaphylaxis [14].
Immediate recognition and accurate diagnosis of anaphylaxis at the point of care, especially
in the setting of an ED, is crucial for initiation of urgent and appropriate care. It was
estimated that 57% of anaphylaxis cases in the ED are misdiagnosed [6]. In our study,
anaphylaxis was diagnosed by ED physicians in a little more than half (66.7%) of cases,
despite fulfilling the criteria of the NIAID/FAAN consensus. Kastner et al. [15] even suggested
that there appears to be excessive caution in using the term anaphylaxis by physicians.
Labelling a case as anaphylaxis matters because it was shown in our study that there were
significantly more patients given epinephrine versus those diagnosed as “hypersensitivity
reaction” or “urticaria.” This observation is consistent with other studies showing that
patients labelled as anaphylaxis at the ED received epinephrine more often, regardless of
the severity of their symptoms than patients diagnosed with other allergy-related diagnoses
[6, 16]. All in all, only about 70% of patients seen in our ED received epinephrine despite
Table 6. Management care plan
Variable

Diagnosed as
Not diagnosed as
Anaphylaxis at ED (n = 70) Anaphylaxis at ED (n = 35)
Other drugs administered aside from epinephrine
Corticosteroid
66 (94.3)
34 (97.1)
Antihistamine
64 (91.4)
34 (97.1)
Bronchodilator
48 (68.6)
18 (51.4)
H2 blocker/proton pump inhibitor
27 (38.6)
25 (71.4)
Referral to an allergist
With referral
32 (45.7)
17 (48.6)
Without referral
38 (54.3)
18 (51.4)
Disposition
Admitted to regular room
56 (80)
24 (68.6)
Admitted to ICU
13 (18.6)
1 (2.9)
Discharged from ED
1 (1.4)
9 (25.7)
DAMA from ED
0 (0)
1 (2.9)
Values are presented as number (%).
ED, Emergency Department; ICU, intensive care unit; DAMA, discharged against medical advice.

https://apallergy.org
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Total
(n = 105)
100 (95.2)
98 (93.3)
66 (62.8)
52 (49.5)
49 (46.7)
56 (53.3)
80 (76.2)
14 (13.3)
10 (9.5)
1 (1)
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fulfilling the criteria of the NIAID/FAAN consensus. Epinephrine was also given in a timelier
manner when anaphylaxis was the diagnosis.
These findings are not unique to our study. Several studies have demonstrated inconsistent
anaphylaxis management in the ED showing even less frequent epinephrine use [17-22], and
significant delay in epinephrine administration [23-27].
In our study, other medications were also given more often than epinephrine. Even
with the lack of evidence that antihistamines and corticosteroids are life-saving in the
acute management of anaphylaxis [28], these were given to more anaphylaxis cases than
epinephrine (93% and 95% respectively).
The route of administration of epinephrine is also part of the current recommendation
for anaphylaxis management. In some studies, lack of knowledge of the correct route of
epinephrine administration was an identified gap, with physicians administering via the
subcutaneous or intravenous route rather than the recommended intramuscular route [20,
21, 23, 29-31]. It was encouraging to see that in our study, the majority of ED physicians gave
epinephrine intramuscularly.
Evidence has shown that delayed epinephrine injection is associated with higher morbidity
and mortality [32]. It was fortunate in our study that despite not receiving epinephrine,
or a significant delay in epinephrine administration, there were no mortalities. This
might be partly due to that fact that these patients were the ones with milder symptoms.
Patients who had a higher risk for mortality and morbidity (respiratory compromise, low
oxygen saturation, and hypotension) were appropriately diagnosed as anaphylaxis and
given epinephrine in a well-timed manner. Data from our study showed that diagnosis of
anaphylaxis at the ED was found to be dependent on the signs and symptoms of wheezing,
oxygen saturation of <95%, abdominal pain, and hypotension. It appears therefore that
patients need to present with moderate to severe signs and symptoms for anaphylaxis to be
consistently diagnosed. The systematic review done by Kastner et al. [15] noted that some
practitioners still think that “shock” needs to be present for anaphylaxis to be diagnosed even
though this has been eliminated from new definitions. Therefore, insufficient knowledge
by medical practitioners to identify the signs and symptoms of anaphylaxis or to correctly
diagnose anaphylaxis is a major gap that needs to be addressed.
As in literature, our study showed that a large percentage of anaphylaxis cases had unknown
triggers. Among those cases with identified triggers from history, the most common agents
found in this study were food and drugs. Unfortunately, we failed to include specific ICD
coding for anaphylaxis secondary to insect sting during the chart review, which could have
affected our results showing only 5 cases triggered by insect stings. Among food triggers,
crustaceans, fish, and peanut were the most common. NSAIDs were the most frequent
among drugs. All these agents are also indicated by WAO to be significant triggers of
anaphylaxis globally [10]. Recent studies have demonstrated that food-induced anaphylaxis
have shown increasing trend not just in pediatric patients but also in all age groups [33, 34].
However, we need to consider possible overestimation of food allergy as a trigger. Currently,
the majority of available data based on self-reporting generally overestimates food allergy
prevalence by a factor of 3 to 4 [35-37]. The study done by Alvarez-Perea et al. [6] confirmed
that after an allergy workup, the trigger differed in many cases from that reported by the
patient or that proposed by the physician in the ED. And in those patients who did not know
https://apallergy.org
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the cause of their reaction, the work up revealed the real trigger. The possible disconnect
between the suspected culprit and real cause of the anaphylaxis, therefore, highlights the
need for improved follow-up care for the patients after the acute event.
Anaphylaxis management guidelines recommend that patients who had previous anaphylaxis
episode be prescribed with epinephrine and referred to an allergist for the long-term
management and prevention of anaphylaxis [38]. In our study, less than half of anaphylaxis
cases were referred to an allergist. Only 1 patient was given a prescription of epinephrine
upon discharge from the ED. Because the onset of anaphylaxis symptoms often occurs in the
community setting [39], at-risk patients should have epinephrine auto-injectors to provide
rapid intramuscular administration of epinephrine [40-42]. There are numerous evidences
demonstrating that delayed medication administration leads to increased risk of progression
to severe anaphylaxis [27, 28, 43, 44]. The dearth of prescription of epinephrine in our
study can be due to the fact that self-injectable epinephrine is actually not available in the
Philippines. This lack of access to self-injectable epinephrine for patients in the Philippines
is a crucial point as this is a cornerstone for long-term management of anaphylaxis. Some
allergists, therefore, instruct caregivers and patients to draw up the dose from a 1-mL ampule.
Others have tried to use unsealed syringes prefilled by the physician with the appropriate
epinephrine dose. Studies have shown however that dose preparation by a lay person from an
ampule can be delayed as much as 3–4 minutes and can be inaccurate [45], and epinephrine
in a prefilled syringe typically degrades within a few months from air exposure [46]. Clearly,
these make-shift solutions are nowhere near adequate.
The limitations of our study are inherent in all studies that use a retrospective method,
with only medical records as the sole source for data. Chart reviews could be lacking in
vital information regarding the clinical assessments during the ED visit including exposure
to allergens, progression of the symptoms, or other parts of the history that could help
differentiate from other diseases including laryngeal or bowel angioedema with concomitant
urticarial for instance. There was no way for us to verify the accuracy of the data in the
medical records, or interact with the patients to probe more on their history.
The incidence of anaphylaxis in this study is 0.03%, comparable to studies in other centers.
Despite available clinical practice guidelines, diagnosis and management of anaphylaxis
continue to be inconsistent. Our study shows that there appears to be a lack of clarity
among ED physicians on how to diagnose anaphylaxis consistently. The labelling of
anaphylaxis is critical as these patients were more likely to receive epinephrine in a timely
manner than those who were given other allergy-related diagnoses. The lack of recognition
of anaphylaxis meant that patients often do not receive first-line epinephrine treatment.
Although epinephrine was given more often to anaphylaxis cases by ED physicians in our
institution as compared to previous studies, the situation still leaves a lot to be desired.
Especially considering that epinephrine administration is the single most important
determinant of outcomes of anaphylaxis. The role of the ED physician cannot be overly
emphasized in the management of anaphylaxis. Discharge from the ED represents the
transition from acute stabilization of the patient to transition to long-term management.
They play a pivotal role in correctly identifying anaphylaxis, and then initiate longterm management during discharge including referral to an allergist and the provision
of epinephrine in an out-patient setting. Further education and quality improvement
programs, and then prospective methods to assess quality of diagnosis and management of
anaphylaxis in the ED are imperative.
https://apallergy.org
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